Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

Executive Summary

Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.

You may also be interested in...



Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.

Bumpy EU Review Ends Well For Selinexor Filing

Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.

Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel